FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP decided that Hycamtin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Hycamtin večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: The dose of Hycamtin to be used depends on the type of cancer that it is being used to treat and the patient's weight and height.
Slovenian: Odmerek zdravila Hycamtin je odvisen od vrste raka, ki ga zdravimo, ter bolnikove telesne mase in višine.
English: It blocks an enzyme called topoisomerase I, which is involved in the division of DNA.
Slovenian: Zdravilo zavira encim, imenovan topoizomeraza I, ki sodeluje pri delitvi DNK.
English: What is the risk associated with Hycamtin?
Slovenian: Kakšna tveganja so povezana z zdravilom Hycamtin?
English: Hycamtin also affects non-cancer cells, which causes side effects.
Slovenian: Zdravilo Hycamtin vpliva tudi na nerakaste celice, kar povzroča neželene učinke.
English: Hycamtin must not be used in patients who are breast-feeding, or in patients who have severe bone marrow depression (low white blood cell and platelet counts) before treatment.
Slovenian: Uporabljati ga ne smejo niti bolnice, ki so noseče ali dojijo, ter bolniki, ki imajo pred začetkom zdravljenja hudo depresijo kostnega mozga (premalo belih krvnih celic in trombocitov).
English: Hycamtin is used on its own to treat patients with:
Slovenian: Zdravilo Hycamtin se uporablja kot samostojno zdravilo za zdravljenje bolnikov:
English: In lung cancer, looking at the results obtained in all three studies, the response rate was 20% (480 patients received Hycamtin).
Slovenian: Rezultati vseh treh študij pljučnega raka so pokazali, da je bila stopnja odzivnosti 20 % (480 bolnikov je prejemalo zdravilo Hycamtin).
English: For the full list of all side effects and restrictions with Hycamtin, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Hycamtin glejte navodilo za uporabo.
English: The fourth study involved 226 women, and compared Hycamtin with paclitaxel (another cancer medicine).
Slovenian: Četrta raziskava je vključevala 226 žensk, v njej pa so zdravilo Hycamtin primerjali s paklitakselom (drugim zdravilom proti raku).
English: • small cell lung cancer, when the cancer has relapsed (come back).
Slovenian: • ob relapsu drobnoceličnega pljučnega raka (ponovitvi bolezni).
English: For lung cancer, Hycamtin can be given as an infusion or, for adults, as capsules.
Slovenian: Pri pljučnem raku se zdravilo Hycamtin lahko daje v obliki infuzije ali pri odraslih v obliki kapsul.
English: Why has Hycamtin been approved?
Slovenian: Zakaj je bilo zdravilo Hycamtin odobreno?
English: One study compared Hycamtin capsules with symptom control alone and another compared Hycamtin as an infusion with cyclophosphamide, doxorubicin and vincristine (a standard combination of chemotherapy).
Slovenian: V prvi študiji so jemanje kapsul zdravila Hycamtin primerjali zgolj z nadzorovanjem simptomov, v drugi študiji pa so zdravilo Hycamtin primerjali kot infuzijo z ciklofosfamidom, doksorubicinom in vinkristinom (običajno kombinacijo pri kemoterapiji).
English: Hycamtin is a cancer medicine that contains the active substance topotecan.
Slovenian: Hycamtin je zdravilo za zdravljenje raka, ki vsebuje zdravilno učinkovino topotekan.
English: When Hycamtin is used on its own for ovarian cancer, it is given by intravenous infusion over 30 minutes.
Slovenian: Če se rak jajčnikov zdravi zgolj z zdravilom Hycamtin, se ta daje z intravensko infuzijo v trajanju 30 minut.
English: When used with cisplatin in cervical cancer, Hycamtin is given as an infusion on days 1, 2 and 3 (with cisplatin given on day 1).
Slovenian: Če se zdravilo Hycamtin uporablja skupaj s cisplatinom za zdravljenje raka materničnega vratu, se daje v obliki infuzije 1., 2. in 3. dan (cisplatin se daje 1. dan).
English: For both ovarian and lung cancer, Hycamtin is given every day for five days with a three-week interval between the start of each course.
Slovenian: Pri raku jajčnikov in pljučnem raku se zdravilo Hycamtin daje vsak dan pet dni zapored, čemur sledi tritedenski premor pred pričetkom novega ciklusa zdravljenja.
English: Hycamtin as an infusion has been studied in more than 480 women with ovarian cancer who had failed one treatment with platinum-containing cancer medicines.
Slovenian: Zdravilo Hycamtin so raziskovali pri več kot 480 ženskah z rakom jajčnikov, pri katerih eno zdravljenje z zdravili proti raku na osnovi platine ni bilo učinkovito.
English: The active substance in Hycamtin, topotecan, is a cancer medicine that belongs to the group ‘topoisomerase inhibitors'.
Slovenian: Zdravilna učinkovina v zdravilu Hycamtin, topotekan, je zdravilo za zdravljenje raka, ki spada v skupino zaviralcev topoizomeraze.
English: Compared with symptom control alone, Hycamtin prolonged survival by
Slovenian: V primerjavi z nadzorom zgolj simptomov se je z zdravilom Hycamtin preživetje podaljšalo za 12 tednov.
English: The third study compared Hycamtin given as an infusion and as capsules.
Slovenian: V tretji študiji so primerjali dajanje zdravila Hycamtin v obliki infuzije in obliki kapsul.
English: Hycamtin as an infusion has been studied in 293 women with advanced cervical cancer, where the effectiveness of a combination of Hycamtin and cisplatin was compared with that of cisplatin alone.
Slovenian: Zdravilo Hycamtin so raziskovali tudi pri 293 ženskah z napredovalim rakom materničnega vratu in primerjali učinkovitost kombinacije zdravila Hycamtin in cisplatina z učinkovitostjo cisplatina kot samostojnega zdravila.
English: Hycamtin given as capsules was as effective as Hycamtin given as an infusion.
Slovenian: Zdravilo Hycamtin v obliki kapsul je bilo enako učinkovito kot zdravilo Hycamtin v obliki infuzije.
English: Doses of Hycamtin may need to be adjusted or treatment delayed, depending on side effects.
Slovenian: Glede na neželene učinke bo morda treba odmerke zdravila Hycamtin prilagoditi ali zdravljenje odložiti.
English: How has Hycamtin been studied?
Slovenian: Kako je bilo zdravilo Hycamtin raziskano?
English: What is Hycamtin used for?
Slovenian: Za kaj se zdravilo Hycamtin uporablja?
English: What is Hycamtin?
Slovenian: Kaj je zdravilo Hycamtin?
English: How does Hycamtin work?
Slovenian: Kako zdravilo Hycamtin deluje?
English: How is Hycamtin used?
Slovenian: Kako se zdravilo Hycamtin uporablja?
English: The European Commission issued a decision on 10 September 2012.
Slovenian: Evropska komisija je odločbo izdala dne 10. septembra 2012.
English: Zinacef is marketed in all EU Member States (except Germany, Latvia, Slovakia and Spain), as well as Iceland and Norway.
Slovenian: Zdravilo Zinacef je na trgu v vseh državah članicah EU (razen v Nemčiji, Latviji, na Slovaškem in v Španiji) ter na Islandiji in Norveškem.
English: The company that markets these medicines is GlaxoSmithKline.
Slovenian: Družba, ki trži ta zdravila, je GlaxoSmithKline.
English: It works by attaching to proteins on the surface of bacteria.
Slovenian: Deluje tako, da se veže na beljakovine na površini bakterij.
English: Zinacef is authorised in the EU via national procedures.
Slovenian: Zdravilo Zinacef je v EU odobreno z nacionalnimi postopki.
English: Why was Zinacef reviewed?
Slovenian: Zakaj je bilo zdravilo Zinacef pregledano?
English: It is also available under other trade names: Curocef, Curoxim, Curoxime, Zinnat.
Slovenian: Na voljo je tudi pod drugimi lastniškimi imeni: Curocef, Curoxim, Curoxime, Zinnat.
English: This prevents the bacteria from building their cell walls, and eventually kills them.
Slovenian: S tem bakterijam prepreči, da bi zgradile celične stene, zaradi česar postopoma odmrejo.
English: The CHMP also harmonised other sections of the SmPC including sections 4.3 (contra-indications) and 4.4 (special warnings and precautions for use).
Slovenian: CHMP je uskladil tudi druga poglavja povzetka glavnih značilnosti zdravila, vključno s poglavjem 4.3 (Kontraindikacije) in 4.4 (Posebna opozorila in previdnostni ukrepi).
English: On 24 May 2012, the European Medicines Agency completed a review of Zinacef.
Slovenian: Evropska agencija za zdravila je 24. maja 2012 zaključila pregled zdravila Zinacef.
English: Having harmonised the indications, the CHMP also harmonised the recommendations on the use of Zinacef in adults and children and in patients with reduced kidney and liver function.
Slovenian: Po uskladitvi indikacij je CHMP uskladil tudi priporočila glede uporabe zdravila Zinacef pri odraslih in otrocih ter bolnikih z zmanjšanim delovanjem ledvic in jeter.
English: Zinacef should be given by injection into a vein over a period of 3 to 5 minutes, by infusion over 30 to 60 minutes, or by deep intramuscular injection, at different doses depending on the condition it is used to treat.
Slovenian: Zdravilo Zinacef se mora dajati z injiciranjem v veno, ki traja od 3 do 5 minut, z infundiranjem, ki traja od 30 do 60 minut, ali z globoko injekcijo v mišico v različnih odmerkih glede na stanje, za zdravljenje katerega se uporablja.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Slovenian: To je privedlo do razhajanj glede uporabe zdravila po posameznih državah članicah, kot je razvidno iz povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo v državah, kjer se zdravilo trži.
English: The CHMP agreed that Zinacef should no longer be used to treat severe ear, nose and throat infections as well as bone and joint infections and gonorrhoea (a sexually transmitted infection caused by bacteria called Neisseria gonorrhoeae), because not enough clinical data are available to support these indications.
Slovenian: CHMP se je strinjal, da se zdravilo Zinacef ne sme več uporabljati za zdravljenje hudih okužb ušes, nosu in grla, okužb kosti in sklepov ter gonoreje (spolno prenosljiva bolezen, ki jo povzroča bakterija Neisseria gonorrhoeae), saj ni dovolj kliničnih dokazov, ki bi podpirali te indikacije.
English: What is Zinacef?
Slovenian: Kaj je zdravilo Zinacef?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Zinacef in the European Union (EU).
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Zinacef.
English: • Community-acquired (acquired outside the hospital) pneumonia.
Slovenian: • zunajbolnišnične pljučnice (pridobljene zunaj bolnišnice);
English: The CHMP concluded that Zinacef should be used in adults and children from birth for the following conditions:
Slovenian: CHMP je zaključil, da se lahko zdravilo Zinacef uporablja pri odraslih in otrocih od rojstva za zdravljenje:
English: Zinacef is an antibiotic used to treat certain bacterial infections, including pneumonia (infection of the lungs), urinary tract infections (infections of the structures that carry urine), soft-tissue infections (infections of tissues just below the skin), infections within the abdomen, as well as to prevent infections during surgery.
Slovenian: Zdravilo Zinacef je antibiotik, ki se uporablja za zdravljenje določenih bakterijskih okužb, vključno s pljučnico (okužba pljuč), okužbami sečil (okužbe struktur, ki proizvajajo in odvajajo urin), okužbami mehkih tkiv (okužbe podkožnih tkiv) in okužbami v trebušni votlini, ter za preprečevanje okužb med kirurškimi posegi.
English: The CHMP also decided that Zinacef should no longer be used in sequential therapy (when switching patients from an injectable to an oral treatment) due to a significant reduction in exposure to the active substance when switching to the oral formulation.
Slovenian: CHMP je odločil tudi, da se zdravilo Zinacef ne sme več uporabljati pri sekvenčnem zdravljenju (pri prehodu bolnikov z injekcij na peroralno zdravljenje) zaradi znatnega zmanjšanja izpostavljenosti zdravilni učinkovini pri prehodu na peroralno farmacevtsko obliko.
English: • Acute exacerbations (flares-up) of chronic bronchitis.
Slovenian: • akutnih poslabšanj (izbruhov) kroničnega bronhitisa;
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Slovenian: CHMP je ob upoštevanju predloženih podatkov in znanstvenih razprav v okviru Odbora menil, da je treba povzetke glavnih značilnosti zdravila, označevanje in navodila za uporabo uskladiti po vsej EU.
English: The active substance, cefuroxime sodium, belongs to the group ‘cephalosporins'.
Slovenian: Zdravilna učinkovina, natrijev cefuroksimat, spada v skupino „cefalosporinov“.
English: • Soft-tissue infections: cellulitis, erysipelas and wound infections.
Slovenian: • okužb mehkega tkiva: celulitisa, erizipela in okužb ran;
English: cardiovascular, and gynaecological surgery (including caesarean section).
Slovenian: kardiovaskularnih in ginekoloških kirurških posegih (vključno s carskim rezom).
English: • Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic,
Slovenian: • za preprečevanje okužb pri gastrointestinalnih (vključno z ezofagealnimi), ortopedskih,
English: On 20 April 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Zinacef in the EU.
Slovenian: Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Zinacef v EU, je 20. aprila 2010 zadevo napotila na CHMP.
English: • Complicated urinary tract infections, including pyelonephritis (kidney infection).
Slovenian: • zapletenih okužb sečil, vključno s pielonefritisom (okužbo ledvic);
English: • Intra-abdominal infections.
Slovenian: • okužb v trebušni votlini;
English: Zinacef was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh).
Slovenian: Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Zinacef potrebna uskladitev.
English: ATCvet code: QI06AA01.
Slovenian: Oznaka ATC vet: QI06AA01.
English: PP MANUFACTURING CORPORATION 175 crossing Boulevard, Suite 200, Framingham, Massachusetts 01702, USA
Slovenian: PP MANUFACTURING CORPORATION 175 Crossing Boulevard, Suite 200, Framingham, Massachusetts 01702, ZDA
English: A moderate and transient local reaction (<2 cm) is commonly observed after the first injection.
Slovenian: Zmerna in prehodna lokalna reakcija (<2 cm) je pogosto opažena po prvem cepljenju.
English: Maternally derived antibodies can negatively influence the immune response to vaccination.
Slovenian: Maternalna protitelesa lahko negativno vplivajo na imunski odziv na cepivo.
English: Date of first authorisation: 17/06/2009.
Slovenian: Datum pridobitve dovoljenja za promet: 17/06/2009 Datum zadnjega podaljšanja : 12/06/2014
English: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above.
Slovenian: Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini razen z zdraviloma omenjenima zgoraj.
English: Pharmacotherapeutic group: immunologicals for Felidae, inactivated viral vaccines for cats.
Slovenian: Farmakoterapevtska skupina: imunološka sredstva za felidae, inaktivirana virusna cepiva za mačke.
English: In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.
Slovenian: V primerih, kjer lahko pričakujemo maternalna protitelesa, je morebiti potrebno še tretje injiciranje v starosti 15
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Slovenian: Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (http://www.ema.europa.eu/).
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.
Slovenian: Zdravila ne smete uporabljajati po datumu izteka roka uporabnosti, navedenega na nalepki po EXP.
English: 3% aluminium hydroxide gel expressed as mg Al3+
Slovenian: 3 % gel aluminijevega hidroksida, izražen kot mg Al3+
English: Special warnings for each target species: Vaccinate healthy animals only.
Slovenian: Posebni previdnostni ukrep za vse ciljne vrste: Cepite samo zdrave živali.
English: Overdose (symptoms, emergency procedures, antidotes):
Slovenian: Preveliko odmerjanje (simptomi , nujni ukrepi, protistrupi ):
English: Active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Slovenian: Aktivna imunizacija mačk, starih osem tednov in več, proti mačji levkemiji za preprečevanje trajne viremije in kliničnih znakov povezane bolezni.
English: Opalescent liquid.
Slovenian: Opalescentna tekočina.
English: Special precautions for use in animals:
Slovenian: Posebni previdnosti ukrepi za uporabo pri živalih:
English: Plastic or cardboard box of 10 vials.
Slovenian: Plastična ali kartonska škatla z 10 vialami.
English: LEUCOGEN suspension for injection for cats
Slovenian: LEUCOGEN suspenzija za injiciranje za mačke
English: T.K.14452, Μεηαμόρθωζη,
Slovenian: Αθηνών - Λαμίας, T.K.14452, Μεηαμόρθωζη, Ελλάδα
English: Plastic or cardboard box of 50 vials.
Slovenian: Plastična ali kartonska škatla s 50 vialami.
English: The transient signs following vaccination such as hyperthermia (lasting 1 to 4 days), apathy and digestive disturbances may also be commonly observed.
Slovenian: Prehodni znaki po cepljenju, kot je hipertermija (ki traja 1 do 4 dni), apatija in motnje prebave so prav tako pogosto opaženi.
English: Protection against persistent viraemia is observed in 73% of cats 3 weeks after their first vaccine injection.
Slovenian: Za komponento levkemije se je zaščita pred trajno viremijo pojavila pri 73 odstotkih mačk tri tedne po prejemu prve injekcije cepiva.
English: Read the package leaflet before use Subcutaneous use
Slovenian: Pred uporabo preberite navodilo Subkutana uporaba
English: Shake the vial gently before use.
Slovenian: Pred uporabo vialo rahlo pretresite.
English: No adverse reactions were observed after an overdose administration of the veterinary medicinal product other than those mentioned in section 6, except local reactions that can last longer (from 5 to 6 weeks at the most).
Slovenian: Po dajanju prevelikega odmerka zdravila za uporabo v veterinarski medicini ni bilo opaziti neželenih učinkov, razen tistih, ki so omenjeni v poglavju 6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
English: Sodium chloride Disodium phosphate anhydrous Potassium dihydrogen phosphate Aluminium hydroxide gel Quillaja saponaria Water for injections
Slovenian: Natrijev klorid natrijev hidrogenfosfat, brezvodni Kalijev dihidrogenfosfat Aluminijev hidroksid (gel) Quillaja saponaria Voda za injekcije
English: Do not mix with any other veterinary medicinal product except FELIGEN RCP or FELIGEN CRP.
Slovenian: Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini razen s FELIGEN RCP ali FELIGEN CRP.
English: A decision to use this vaccine before or after another veterinary medicinal product therefore needs to be made on a case by case basis.
Slovenian: Zato se za uporabo tega cepiva pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera do primera.
English: No adverse reactions were observed after an overdose administration (2 doses) of the veterinary medicinal product other than those mentioned in section 4.6 except local reactions that can last longer (from 5 to 6 weeks at the most).
Slovenian: Po dajanju prevelikega odmerka (2 odmerkov) zdravila za uporabo v veterinarski medicini ni bilo opažena neželenih učinkov, razen tistih, ki so omenjeni v poglavju 4.6, z izjemo lokalnih reakcij, ki lahko trajajo dlje časa (od 5 do 6 tednov največ).
English: Type I glass vials containing one dose (1 ml) of the vaccine closed with a 13 mm-diameter butyl elastomer stopper and aluminium capsule.
Slovenian: Steklena viala tipa I, ki vsebuje en odmerek (1ml) cepiva, zaprta z zamaškom iz butil elastomera, premera 13 mm in z aluminijasto kapsulo.
English: Vaccine against feline leukaemia.
Slovenian: Cepivo proti mačji levkemiji.
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP and FELIGEN RCP.
Slovenian: Na voljo so podatki o varnosti in učinkovitosti, ki dokazujejo, da se to cepivo lahko zmeša in daje s FELIGEN CRP in FELIGEN RCP.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Box of 10 or 50 vials
Slovenian: PODATKI NA ZUNANJI OVOJNINI Škatla z 10 ali 50 vialami
English: Per dose of 1 ml:
Slovenian: Vsak odmerek po 1 ml vsebuje:
English: The onset of immunity has been demonstrated from 3 weeks after the primary vaccination.
Slovenian: Začetek imunosti je dokazan od 3-eh tednov po prvem cepljenju.
English: After the primary vaccination course, the duration of immunity lasts for one year.
Slovenian: Po prvem krogu cepljenja je trajanje imunosti eno leto.
English: Shelf life after first opening the immediate packaging: use immediately.
Slovenian: Rok uporabnosti po prvem odprtju stične ovojnine: porabite takoj
English: De-worming at least 10 days prior to vaccination is recommended.
Slovenian: Priporočljivo je mačke razglistiti vsaj 10 dni pred cepljenjem.
English: Special precautions for use in animals De-worming at least 10 days prior to vaccination is recommended.
Slovenian: Priporočljivo je razglistiti mačke vsaj 10 dni pred cepljenjem.
English: Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with FELIGEN CRP or FELIGEN RCP.
Slovenian: Razpoložljivi podatki o varnosti in učinkovitosti so pokazali, da se to cepivo lahko zmeša in daje z zdravilom FELIGEN CRP ali FELIGEN RCP.
English: Administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.
Slovenian: Odmerek (1ml) zdravila za uporabo v veterinarski medicini dajte subkutano po naslednjem programu cepljenja.
English: 1055 Budapest Magyarország Teл: +36703387177
Slovenian: Teл: +36703387177
English: Shake the vial gently and administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.
Slovenian: Vialo rahlo pretresite in subkutano dajte odmerek zdravila za uporabo v veterinarski medicini po naslednjem programu cepljenja.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial label
Slovenian: PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
English: Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years.
Slovenian: Po prvem poživilnem cepljenju leto dni po prvem krogu cepljenja, se lahko izvaja nadaljnja cepljenja v intervalih po tri leta.
English: Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated.
Slovenian: Po prvem poživilnem cepljenju leto dni po prvem krogu cepljenja je dokazano trajanje imunosti 3 leta.
English: A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
English: Primary vaccination: - first injection in kittens from eight weeks of age - second injection 3 or 4 weeks later.
Slovenian: - drugo injiciranje 3 ali 4 tedne kasneje.